Summary In this study, a fixed regimen of prednisolone for the treatment of acute nerve fu nction impairment (NFl) in leprosy patients was developed and introduced at field level in one area (Thakurgaon) of the Danish-Bangladesh Leprosy Mission's field in NW Bangladesh. The assessment, management and fo llow-up of patients was undertaken by leprosy control supervisors and physiotechnicians_ One hundred patients were treated and fo llowed up 6-8 months after completion of a 4-month course of prednisolone_ At a level of change of 2 points (where a change of at least 2 points in the motor/sensory score was taken to indicate a change of status, i_e_ fu ll or partial recovery, or deterioration), 42/65 (64-6%) patients with sensory loss experienced some sensory recovery at completion of prednisolone treatment, and 40/65 (61-5%) at 6-8 months' fo llow-up_ 41/85 (48-3%) of patients with motor loss experienced improvement, and 42/85 (49-4%) at fo llow-up_ Analysis of the mean scores at start of prednisolone treatment, completion and at fo llow-up using Student's (-test showed highly significant (p < 0-001) differences between scores before and after treatment. The benefit is maintained as seen after a period of 6-8 months fo llow-up_ It was concluded that treatment of acute nerve fu nction impairment at field level by paramedical workers, using a standardized regimen of prednisolone is fe asible, practical and effective_
is confined to a hospital setting. Unfortunately, a proportion of patients who would benefit fr om corticosteroid administration are for various reasons unable or unwilling to be admitted to hospital. As a result they go on to develop nerve function impairment (NFl) with resulting disability and handicap. This problem was phrased by Becx Bleumink et al. as fo llows: 'When the management of patients on corticosteroids is the responsibility of medical offi cers only, we will deprive many patients of adequate treatment fo r their reactions. ' I A recent study of a cohort of new patients in Bangladesh that started MDT in 1990 shows that over a third of cases with recent NFl were not treated with corticosteroids for the above reason.
2 Introduction of treatment in the field of recent NFl using standardized corticosteroid regimens has been hesitant. Organizational and logistic problems are one reason, reservations concerning side-effects of corticosteroids, and placing the responsibility of their management into the hands of paramedical workers, another.
It is well known that corticosteroids are effective in the treatment ofleprosy reactions and acute NFl in leprosy. I , 3 -7 It is generally agreed that in order to be effective, corticosteroids must be administered within 6 months of an episode of NFL 1, 8 As stated above, attention has been drawn to the need for such treatment to be given by suitably trained field workers in order for the maximum number of patients to receive benefit. 1 , 9
Several standardized or semi-standardized regimens for the treatment of NFl have been proposed using prednisolone. For example, 40 mgjday tapering over 12 weeks for paucibacillary (PB) patients and 20 weeks for multibacillary (MB) patients. 9 Another regimen recommended is 25 mg prednisolone daily, reducing by 5 mg per month. 6 For the latter regimen it was recommended that the starting dose should be higher for 'severe reactions' .
All of the studies referred to above comment on the absence of serious side-effects of prednisolone in relatively long courses. A recent meta-analysis reviewing 93 articles and 6602 patients fo und that peptic ulceration was not significantly associated with prolonged steroid use. 10 In the meta-analysis, a mean daily dose of 35-mg prednisolone fo r a mean duration of 64 days was given-comparable to the courses used for the treatment of leprosy reactions. 11 Other side-effects including diabetes, hypertension, psychosis and dermatological side-effects were fo und to be significantly associated, but bacterial sepsis, osteoporosis and tuberculosis while occurring more frequently in the treatment group, did not achieve statistical significance. Overall, a picture of relative safety emerged fr om this meta-analysis.
In 1994 the Danish-Bangladesh Leprosy Mission (DBLM) began with the imple mentation of a fully field-based programme of the treatment of leprosy reactions and acute NFL The decision to give corticosteroids to individual patients was delegated to the lowest appropriate level, that of leprosy control supervisor (LCS) and physiotechni cian (PT). A protocol for management of reactions was developed by a committee, training provided, and a 7-month pilot programme initiated. This study reports on the outcome of this initial programme after the first year's experience.
Methods

LOCATION
The study was conducted at the Danish-Bangladesh Leprosy Mission (DBLM) ill Nilphamari, in NW Bangladesh. DBLM is a private organization involved in a vertical leprosy programme situated in a highly endemic area (prevalence: 5/1000). 1 2 The field programme is geographically divided into three 'fields', each with separate reporting. One area, the Thakargaon field, was selected for this study. It covers the two districts of Thakargaon and Panchagar with a total area of 3,214km 2 and 1,7 million population (1991 census).
ORGANIZATIONAL STRUCTURE
The DBLM Thakargaon field is divided into 6 'blocks', each with its own staffing of leprosy control assistants (LCA) who work under the direction of a leprosy control supervisor (LCS), responsible for that block. In turn, the LCS relates to the leprosy control officer (LCO) who is responsible for the entire field. The LCO relates directly to the field director, who is a medical officer. In addition, there are physiotechnicians (PT) assigned to the field who visit on every clinic day and who are involved in nerve fu nction testing, the teaching of special exercises and health education. New leprosy cases are charted by LCAs who also take skin smears. The cases are then confirmed by the LCS, and MDT is given at his direction. All cases at every clinic visit (during multidrug therapy (MDT) and surveillance) have sensory testing and quick muscle testing carried out by the LCA. If any abnormality is fo und, the case is referred to the PT and LCS for confirmation. Equivocal results were not accepted for corticosteroid treatment and in such cases were reassessed the fo llowing month.
NER VE FUNCTION TESTING
Sensory testing was carried out using a ball-point pen as described by Watson. 13 Testing took place at 12 standard points on each hand palm and 11 standard points on each fo ot sole. Either partial or complete anaesthesia was taken as a positive finding. The sensory score is calculated by counting the number of sensory points which were abnormal. Motor function testing of the facial, radial, ulnar, median and lateral popliteal nerves was carried out by means of 'quick muscle testing' (QMT) and graded according to a revised MRC scale 1 4 ( Table 1 ). The regular MRC score was reversed so that zero always indicated normality for both motor or sensory testing. The reversed score is referred to as the DBLM score. Details of muscles tested are also given in Table 1 . Each muscle or muscle group tested is assigned a DBLM score up to a maximum of 5.
Corneal sensation testing was performed in those patients who were observed to blink infrequently (less than 5 times per minute), but the evaluation of this parameter is not included in this study.
ACUTE NFl TREATMENT PROTOCOL
The complete guidelines as used for this study are reproduced in the Appendix. According to these guidelines leprosy reactions and NFl are graded according to severity and treatment assigned accordingly. Patients with signs of acute NFl were given 40-mg prednisolone daily and tapered off over 4 months in the field. This was Abduction of thumb Radial nerve:
Wrist extension Lateral popliteal nerve: Dorsiflexion of foot; Eversion of foot defined as the reduction by 1 point in the MRC muscle strength grade of any of the movements routinely tested in the QMT; the loss of 1 standard sensory point on the hands or fe et; or the development of corneal anaesthesia. Acute was taken to mean occurring within the previous 6 months. Other signs of leprosy reaction or NFl may or may not have been present, e.g. inflamed skin patches, painful nerves.
Patients with acute NFl according to the criteria of DBLM grade 2 (see Appendix) seen between July 1994 and January 1995 were included in this study. There were no patients with impairments according to DBLM grade 3, although patients whose nerve function deteriorated after starting field prednisolone were admitted during treatment. Patients with signs of Type I reaction or neuritis without signs of NFl (DBLM grades la and 1 b) were excluded, even if they were treated with prednisolone. Out of the initial group of 103, one died and two were lost to fo llow-up. A total of 100 patients were included in the study group. Restoration of sensory or motor score to zero (normality). Partial improvement in sensory or motor score. No overall change in sensory or motor score. Deterioration in sensory or motor score. Table 2 shows the general data of the 100 patients who received a standardized regimen of prednisolone in the field. The mean age of patients was 35· 3 years (median: 34· 5 years, range: 8-70 years). The distribution of study patients according to the Ridley-Jopling classification was as follows: BT: 64; BB: 12; BL: 13; LL: 7; PN: 4.
The outcome of sensory fu nction amongst the study group is shown in Table 3 , the outcome of motor function is shown in Table 4 . Outcome has been expressed at different 'sensitivity levels'. Where a change of 2': 1 point in the sensory score was taken as Table 3 . Outcome of sensory fu nction amongst study group patients with acute sensory loss expressed at three levels of sensitivity (n = 65) *Sensitivity levels Outcome is expressed at 3 sensitivity levels. These indicate numbers of patients whose sensory scores changed either 2':1, 2':2 or 2':3 points relative to the score at start of prednisolone therapy. JOO *Sensitivity levels Outcome is expressed at 3 sensitivity levels. These indicate numbers of patients whose motor scores changed either :::: I, :::: 2 or :::: 3 points relative to the score at start of prednisolone therapy.
significant, a total of 81·6% of patients showed sensory improvement after completion of prednisolone therapy (38'5% with fu ll recovery), a percentage maintained with 77% improved (38'5% fu ll) after 6-8 months of fo llow-up . With a change of?: 2 points in the sensory score, this was 64·6 % (29'2% fu ll) at completion of therapy and 61·5% (29'2% fu ll) at 6-8 months; at the ?: 3-point change in sensory score there was 49 ·2% (24'6% fu ll) at end of therapy and 50·8% (23·1 % full) at fo llow-up . Thus, the level of improvement in sensory fu nction was of the order of 50-60% at more conservative levels of sensitivity, a level which was maintained 6-8 months after the end of Table 5 . Total sensory scores and mean sensory scores at diagnosis of NFl (I), completion of prednisolone therapy (II), and at follow-up (III), with significance of mean differences calculated using I-test. Complete anaesthesia of hands and fe et in one patient would score 46, with a best possible total score of 0 (Table 5) shows highly significant differences for mean scores both immediately after prednisolone and at 6-8 months' fo llow-up using the Student t-test (p < 0·001). The only exception was for the small group of patients with NFl of 4-6 months' duration (n = 11) where there was no significant differences between the mean scores before treatment and at either time after treatment. Although this number is too small to draw statistical conclusions fr om, it suggests that there may be less recovery in patients with more established NFL There was no significant difference between mean sensory scores immediately after prednisolone treatment and at 6-8 months' fo llow-up (p = 0·372), indicating that sensory recovery is maintained. Turning to motor recovery, there is also a good level of response, but less marked than for sensory outcome. At the 2: 1 point change of motor fu nction score there is a 93 % (6 1·2% fu ll) overall improvement at the end of prednisolone therapy and 90·6% (70·6% fu ll) at end of fo llow-up. However, at the 2: 2-point level it is 48·3% (3 1·8% fu ll) and 49-4% (40 % fu ll) respectively. At the 2: 3 level it is 25·9% (16·5% full) and 28·3% (7· 1 % fu ll) respectively. Thus the level of motor recovery was in the range 25-50% at the 2:2 or 2:3 point levels in change of motor fu nction score. Again, analysis of mean differences using the Student t-test between mean motor scores before and after prednisolone treatment showed a highly significant difference with p < ·001. Interestingly, the longer duration NFl group (4-6 months' duration) did show a significant difference in mean scores before and after treatment (p = 0·001), unlike the parallel sensory group. Again, there was no significant difference between mean motor scores immediately after prednisolone treatment and at 6-8 months' fo llow-up (p = 0· 361), indicating that motor recovery, like sensory recovery, is maintained.
Discussion
This study is primarily concerned with the fe asibility and effectiveness of treating acute NFl with a standardized regimen of prednisolone in the field. A single standardized regimen for the treatment of NFl was developed based on the recommendations made by Rose & Waters 9 as well as Becx-Bleumink. 1 This was taught to field staff in the DBLM Thakurgaon field and implemented, using experienced leprosy control super visors and physiotechnicians as the key persons at field level to assess patients and give treatment.
Results of the field treatment of NFl with prednisolone were analysed in two separate ways: the first method described change in nerve fu nction in terms of full and partial recovery, same (no change) and deterioration, using three different levels of sensitivity in defining a relevant change in sensory or motor function score. In the second method mean differences of total sensory and motor fu nction scores at the time of diagnosis, completion of prednisolone therapy and after fo llow-up were compared and statistically analysed. Both approaches demonstrate marked improvement in both sensory and motor fu nction, even when applying the very strict criteria of a change of 2:3 points in the sensory and motor fu nction scores. This conclusion applies to the overall study group . Only in patients with NFl of 4 to 6 months duration, improve ment in the sensory scores in marginal, if at all (Table 5 ). There does seem to be improvement in the motor scores in this group (Table 6 ). The size of the study was too small to identify risk factors for nerve damage and to look at the response of subsets of patients to treatment. However, that is the subject of a large prospective cohort study into acute nerve damage now running in DBLM (Bangladesh acute nerve damage study).
The results of this study compare well with those of Van Brakel & Khawas. 7 In that study touch sensibility testing was performed using a nylon monofilaments giving a force of 10 g for the hands, and a thicker one giving a force of 75 g for the sole of the fo ot, whereas DBLM uses the ball-point pen in the field. The criteria they used for change in sensory and motor fu nction are a difference of more than 1 point (or 22) on the touch sensibility test (TST) or voluntary muscle test (VMT). Van Brakel & Khawas analyse in depth changes seen in individual nerves and also describe time trends and prognostic factors, elements outside the scope of the study presented in this paper. Nevertheless, the overall picture of improvement in sensory scores (app. 65%), and motor fu nction scores (app. 50%) at a change of 22 point in score, is similar. The improvement was maintained over a follow-up period of more than 6 months.
A number of patients experienced deterioration in nerve fu nction during the period, including a few patients who initially fully recovered. All of these patients required a second course of prednisolone or a hospital admission. However, given that a fixed regimen was used (the field staff were not given freedom to alter it at will) the results can still be considered as very satisfactory.
In this study, no cases of peptic ulcer, TB, sepsis or psychosis occurred. Blood pressure was not routinely measured by field staff and urine glucose was also not tested. Dermatological side-effects including acne, tinea corporis and cushingoid fat redistribution occurred only in a small number of patients. The overall experience has been very positive with the field staff enthusiastic towards the programme despite the increased workload for them. They reported good compliance from patients once they understood that they were avoiding a hospital admission; positive feedback from patients recovering lost nerve function; and the staff themselves felt happy about their increased responsibility. Since the field treatment of reactions has been extended to the whole of DBLM there has been a marked drop in hospital admissions, freeing beds which are now being used for an increasingly busy reconstructive surgery programme.
We share the conclusion of Van Brakel & Khawas 7 that fu rther research is needed to optimize the results of treatment of acute NFL There are still too many patients for whom the present detection and treatment options are not sufficient, and who remain with impairments after successful treatment of their leprosy infection with MDT. On the other hand we are strongly convinced that as a first step, and pending fu rther improvements in detection and therapy, the present knowledge and possibilities of early detection and treatment of NFl should be made available for all leprosy patients. This study shows that field treatment of NFl with a standardized regimen of prednisolone, administered by paramedical staff is fe asible, practical and effective.
• Weekly review at home I month, then 2 weekly 
